8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

Acrivon Therapeutics filed an 8-K reporting corporate governance and shareholder-vote updates. The filing covers Item 5.02 and Item 5.07, indicating changes involving directors/officers and the results of matters submitted to security holders, with exhibits included. The report is largely procedural and does not provide operating results, revenue, guidance, or a major strategic transaction, so the market impact appears limited and informational rather than fundamentally price-driving. Investors may view it as part of routine compliance disclosure for a small-cap biotech rather than a catalyst for earnings or clinical data.